Refine by
Disease Symptoms Articles & Analysis
21 news found
The presence of mold can pose a health risk to people with a mold allergy, damaged lungs or compromised immune systems, the CPSC said. According to the Centers for Disease Control and Prevention, symptoms of mold exposure can vary but typically include burning eyes, respiratory problems such as coughing and wheezing, and skin irritations. ...
New results from the Phase III ARASENS trial evaluating quality of life (QoL) and patient-relevant endpoints for darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) show that, in addition to extending overall survival (OS), darolutamide has a strong tolerability profile and ability to maintain patient QoL with ...
ByBayer AG
It is being used to target multiple fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), and Hermansky-Pudlak Syndrome, a rare ‘orphan disease’ with no known treatment. ...
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
Cardiac CT combined with SQuEEZ analysis software can provide clinicians with a normalized measurement to determine the answer to the first and most important clinical question a cardiac surgeon needs to know for patients with Cardiovascular Disease (CVD) symptoms— “Is the contractile function normal or not ...
Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disorders and disease pathology, progression, and symptoms. The company is advancing a pipeline of “microbial-inspired ...
Asthma is one of the most common chronic diseases in children. Up to 85% of children with asthma may have type 2 inflammation and are more likely to have higher disease burden. ...
Earlier studies in animal models were the basis for the foundational concept that metabolites produced by intestinal bacteria can circulate in the bloodstream and affect the pathology, progression, and symptoms of neurodegenerative diseases and neurodevelopmental disorders. Axial Therapeutics was founded based on this research as well as additional preclinical ...
The ongoing phase 1 and 2 clinical trials are multisite dose-escalation studies evaluating the safety and the efficiency of the IBIO123 immunotherapy administered by inhalation to infected patients with mild-to-moderate symptoms. A similar study among patients with severe presentation of the disease (hospitalized cases) is planned to begin in Q1 2022 in multiple ...
Axial is advancing a pipeline of small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disease pathology, progression, and symptoms. The company’s drug discovery approach is rooted in the groundbreaking research of its co-founder and chief ...
“Eosinophilic esophagitis is a rare and chronic disease with very limited treatment options. Esocap supports the first EoE awareness campaign for this debilitating disease. ...
“We thank David for his commitment and tireless effort over the past four years, taking Axial from an idea to a company poised to enter Phase 2B in autism and with a robust pipeline of innovative programs in Parkinson’s disease and oncology,” said Dr. Campbell. Axial’s unique focus on targeting the gut as a means to treat CNS diseases and ...
Localization and ablation of drivers perpetuating AFib has been at the forefront of cardiovascular disease research but has not led to any radical changes to-date. The Volta mapping system is intuitive, user-friendly and shows promise to potentially reduce inter-operator variability in the analysis of procedural data without lengthening either the diagnostic or therapeutic ...
This clinical trial is sponsored by the National Institutes of Health’s (NIH) National Center for Complementary and Integrative Health (NCCIH).* Besides the primary endpoint for Vh:Cd, other endpoints include: (i) histologic measure of intraepithelial lymphocytes (IEL), (ii) symptom response utilizing the celiac disease symptom diary (CDSD) ...
CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). The European Union Patent Number 12839978.9 was awarded on February 2, 2019, followed closely by the U.S. Patent on June 7, 2019 (patent application number 14/350,991). Both patents are entitled “Methods for Evaluating ...
In combination with the funding and the exclusive license for the SERY technology, we are in a prime position to provide innovative solutions for a disease which has long been neglected.” “Currently available MSA therapies merely ease symptoms as disease progression continues. Our goal with the development of anle138b is to stop ...
Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. People develop NASH when early liver disease, characterized by too much fat in the liver, is exacerbated by ...
Asthma is a disease of the lung in which the airways are inflamed. Because of this inflammation, the airways can easily narrow, causing symptoms such as wheezing, coughing, chest tightness, and difficulty breathing. ...
CardioWise, Inc. has completed National Science Foundation (NSF) Phase I and IB Small Business Innovation and Research (SBIR) grants that continued the development and commercialization of a non-invasive analysis method for detection of heart disease. The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the ...
The bacteria got its name in 1976, when people at a Philadelphia convention of the American Legion suffered from an outbreak of the disease. Although this type of bacteria was around before 1976, more cases of the illness due to Legionnaires' disease are being detected now. ...